Executive Chairman and CEO Miguel Martin stated that the revised bid forces shareholders to sacrifice future upside at a discount, effectively asking them to fund the acquisition using Aurora’s own balance sheet. The company maintains that the offer relies on Curaleaf shares at an inflated valuation, exposing Aurora investors to potential market volatility. Aurora is currently exploring strategic alternatives, including potential partnerships or continuing as a stand-alone entity, and has entered discussions with multiple third parties.

Shareholders are instructed to take no action regarding the offer, which remains open until December 4, 2026. The board warns that tendering shares prematurely could undermine the potential for a superior outcome. Detailed reasons for the rejection, supported by an updated fairness opinion from financial advisors, are available through the company’s dedicated investor portal and regulatory filings. Investors seeking guidance are encouraged to contact Kingsdale Advisors.